DUBLIN – Octimet Oncology NV, a spinout from the Janssen Pharmaceutica NV arm of Johnson & Johnson, raised €11.3 million (US$12 million) in a series A round for clinical development of a drug that hits c-Met (cellular mesenchymal-epithelial transition factor), a receptor tyrosine kinase that is one of the most beguiling targets in cancer.